AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 201 min read$ONCY

Oncolytics Biotech to Present REO 033 Trial-in-Progress at ESMO Highlighting Pelareorep in RAS‑mutant MSS mCRC

Oncolytics Biotech will present REO 033 trial data at ESMO 2026, focusing on pelareorep for RAS-mutant mCRC. The Phase 2 study compares pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab, with 30 patients per arm. Primary endpoint is ORR, with OS, PFS, DOR, and safety as secondary endpoints. Recent FDA interactions may enable a pivotal expansion for accelerated approval.

Original reporting
tradingview.com
Published Oct 20, 2026, 1:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Oncolytics Biotech to Present REO 033 Trial-in-Progress at ESMO Highlighting Pelareorep in RAS‑mutant MSS mCRC — source image
Source · tradingview.com
Decision brief

The 30-second read

$ONCYNeutralMed
01

Why it matters

The abstract signals progress toward a pivotal trial, which could accelerate regulatory approval if early results are positive.

02

Market read

The announcement is a primary disclosure for ONCY, offering new information that may influence short‑term trading and longer‑term valuation.

03

What to watch

Potential competition from other oncolytic agents and the need for larger Phase 3 data could temper expectations.

Relevance 8/10Novelty 8/10Timing: today

Background

Oncolytics Biotech (ONCY) is a clinical-stage biotech focused on oncolytic virus therapy. The REO 033 trial targets RAS‑mutant, MSS metastatic colorectal cancer.

Company-level read

Ticker impact

$ONCYNeutralMedium confidence
Context

Oncolytics Biotech announced a Phase 2 REO 033 trial-in-progress abstract at ESMO, detailing a randomized study of pelareorev + FOLFIRI + bevacizumab versus control.

Expected impact

potential modest upside as the market prices in trial progress and possible regulatory pathway

Evidence & confidence

Early-phase data are not yet efficacy results, but the FDA interaction and planned pivotal expansion suggest upside potential without immediate catalyst strength.

Market effects

Sector

May boost sentiment in the oncolytic virotherapy and broader biotech sector as investors watch for early trial signals.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global impact; relevance confined to specialty oncology investors.

Counterpoint

What could challenge this read

If the trial fails to meet endpoints, the stock could face sharp downside despite hype.

Key entities

  • company
    Oncolytics Biotech

    US-listed biotech developing pelareorep.

  • event
    ESMO 2026

    European Society for Medical Oncology annual meeting where the abstract is presented.

Read at source← All news

StoryOncolytics presents REO 033 colorectal cancer trial at ESMO 2026

Related articles

OCT 20
$ONCYMedAI 8/10

An earlier colorectal cancer study reported 17 months before worsening, vs. 6 historically.

Oncolytics Biotech (Nasdaq: ONCY) presented a trial-in-progress abstract at ESMO Congress 2026 for its REO 033 study, evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line RAS-mutant MSS mCRC. The study aims to validate earlier efficacy signals from the REO 022 study, which showed improved outcomes compared to historical standards. The company plans to expand the trial to support potential accelerated approval.

stocktitan.net2 min
OCT 14
$ONCYLow

Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment

Oncolytics Biotech (ONCY) updated its GOBLET study timelines, expecting final PanCAN grant payment in Q4 2026. Cohort 4 data is due in Q4 2026, with Cohort 5 results in H1 2027. Median overall survival in Cohort 4 exceeded expectations, and the company is winding down study infrastructure while monitoring remaining patients. ONCY is developing pelareorep for gastrointestinal cancers and is currently trading at $0.55, up 13.72%.

rttnews.com2 min
OCT 14
$ONCYLow

Oncolytics reports GOBLET study enrollment complete

Oncolytics Biotech (NASDAQ:ONCY) completed enrollment in its GOBLET Phase 1/2 study and expects final grant payment this quarter. Cohort 4 results are due in Q4 2026, with Cohort 5 results in H1 2027. The study, conducted in Germany, focuses on pelareorep-based therapies for cancer. The company plans to use data to guide future strategies. Pelareorep has Fast Track designation for colorectal, anal, and pancreatic cancer.

investing.com1 min
OCT 14
$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min